MediWound (NASDAQ:MDWD) Director Buys $49,907.07 in Stock

MediWound Ltd. (NASDAQ:MDWD) Director David Morton Fox bought 3,537 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average cost of $14.11 per share, with a total value of $49,907.07. Following the transaction, the director owned 22,283 shares in the company, valued at approximately $314,413.13. This represents a 18.87% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

MediWound Stock Performance

MDWD opened at $14.45 on Friday. The firm has a 50 day moving average price of $16.39 and a 200 day moving average price of $17.31. The company has a market cap of $185.68 million, a PE ratio of -6.39 and a beta of 0.16. MediWound Ltd. has a 1 year low of $13.54 and a 1 year high of $22.09.

MediWound (NASDAQ:MDWD) last posted its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same quarter in the prior year, the company earned ($0.07) EPS. On average, sell-side analysts predict that MediWound Ltd. will post -2.49 earnings per share for the current year.

Institutional Trading of MediWound

Large investors have recently bought and sold shares of the company. Quarry LP acquired a new stake in MediWound in the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets grew its position in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares in the last quarter. Russell Investments Group Ltd. grew its position in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in MediWound in the fourth quarter valued at approximately $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Oppenheimer reaffirmed an “outperform” rating and issued a $32.00 price objective (down from $33.00) on shares of MediWound in a research report on Wednesday, May 27th. Finally, Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, MediWound has a consensus rating of “Hold” and a consensus price target of $34.00.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.